Controversies on Combined Androgen Blockade for Prostate Cancer
Publisher
Springer Singapore
Reference23 articles.
1. Klotz L, Schellhammer P, Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int. 2004;93(9):1177–82. 2. Allen JM, O’Shea JP, Mashiter K, Williams G, Bloom SR. Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist. Br Med J. 1983;286(6378):1607–9. 3. Warner B, Worgul TJ, Drago J, Demers L, Dufau M, Max D, Santen RJ. Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer. J Clin Invest. 1983;71(6):1842–53. 4. Nicholson RI, Walker KJ, Turkes A, Turkes AO, Dyas J, Blamey RW, Campbell FC, Robinson MR, Griffiths K. Therapeutic significance and the mechanism of action of the LH-RH agonist ICI 118630 in breast and prostate cancer. J Steroid Biochem. 1984;20(1):129–35. 5. Jiang G, Stalewski J, Galyean R, Dykert J, Schteingart C, Broqua P, Aebi A, Aubert ML, Semple G, Robson P, Akinsanya K, Haigh R, Riviere P, Trojnar J, Junien JL, Rivier JE. GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6. J Med Chem. 2001;44(3):453–67.
|
|